In VIvo CAR-T
In Vivo CAR-T Technology Poised to Expand Access and Indications
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-25-NI-07Aug 11, 2025
Cell Therapy
Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe
Cryoport
PR-10-24-NI-95Nov 12, 2024
Cell Therapy Manufacturing
Rethinking Cell Engineering for Cell Therapy Manufacturing
Todd Sulchek, Ph.D
CellFE
PAO-11-23-CL-03Dec 13, 2023
Cell Therapy
Creating Efficiencies in Engineered Cell Therapy Development with Comprehensive Electroporation Support
Sarah Meeks, Ph.D.
MaxCyte
PAO-09-23-CL-09Sep 28, 2023
Cell Therapy
Moving from Autologous to Allogeneic Cell Therapies: Drivers and Hurdles
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-01-23-NI-01Jan 31, 2023
Cell Therapy
Bedside Cell Therapies: Point-of-Care Manufacturing Is Slowly Becoming a Reality
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.
Pharma's Almanac
PAO-11-022-NI-08Nov 15, 2022
Cell Therapy Manufacturing
RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies
AGC Biologics
PR-M08-22-03Aug 16, 2022
Cell Therapy
A PODular Therapies-as-a-Service Approach To Fundamentally Change the CAR-T Cell Therapy Landscape
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-022-CL-05May 31, 2022
New Facility
AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus
AGC Biologics
PR-M05-22-13-359May 18, 2022